Cases & Deals

Pfizer acquires Serenex, Inc

Clients Pfizer, Inc.

Jones Day acted as tax counsel to Pfizer, Inc. in its acquisition of Serenex, Inc., a privately-held biotechnology company. As per the agreement, Pfizer acquired the rights to SNX-5422, an oral Hsp90 inhibitor currently in Phase 1 trials for the potential treatments of tumors and hematological malignancies.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.